Journal · Diabetes · Updated 22 November 2026
Diabetes Therapy
Read Diabetes Therapy articles on DeepDyve. No university library needed.
Diabetes Therapy has published since 2010 and covers the treatment and education of diabetes and related disorders, with recent papers on incretin drugs and heart and kidney outcomes, gut bacteria and metabolic health, and glucose monitoring in India. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Diabetes Therapy at a glance
- Full title
- Diabetes Therapy
- Abbreviation (NLM)
- Diabetes Ther
- Publisher
- Springer Nature
- Print ISSN
- 1869-6953
- Online ISSN (eISSN)
- 1869-6961
- First published
- 2010
- Access model
- Open access since 2010
Ways to access Diabetes Therapy
All of the articles Diabetes Therapy published from January 1 to November 20, 2026 are open access and free to read. For older articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 100% of Diabetes Therapy articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Diabetes Therapy. Check its journal list and whether it offers remote access.
- DeepDyve. Read Diabetes Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Diabetes Therapy’s 2025 Journal Impact Factor is 4.2, and its 5-year Impact Factor is 3.7.
4.2
Journal Impact Factor (2025)
3.7
5-year Impact Factor (2025)
1.9M
Downloads (2025)
Source: journal metrics on the Diabetes Therapy homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Diabetes Therapy research worth reading
Published January to February 2026. Summaries describe what the authors report.
-
Gut Microbiota and Metabolic Health: From Dysbiosis to Therapeutics
The authors review how imbalances in gut microbes contribute to obesity, type 2 diabetes and metabolic syndrome, and report that while GLP-1 receptor agonists and bariatric surgery reshape the microbiota, direct microbial treatments give variable results in human trials.
Sasidharan Pillai et al. · Diabetes Therapy, published online February 28, 2026 · DOI 10.1007/s13300-026-01851-x
-
Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes
Reviewing trials including SELECT, FLOW, SOUL and SURPASS-CVOT, the authors report that long-acting GLP-1 receptor agonists reduce major cardiovascular events, death and kidney outcomes in type 2 diabetes regardless of baseline HbA1c, shifting care toward cardiorenal risk reduction.
Miramontes-González et al. · Diabetes Therapy, published online January 5, 2026 · DOI 10.1007/s13300-025-01829-1
-
Modern Management of CKM Syndrome: Use of GLP-1 Receptor Agonists in a Multidisciplinary Setting—Expert Group Recommendations from Kuwait
A panel of Kuwaiti endocrinologists, cardiologists and nephrologists reports gaps in screening, care coordination and access to GLP-1 receptor agonists for cardiovascular–kidney–metabolic syndrome, and recommends earlier diagnosis, integrated care across specialties and broader drug access.
Aldahi et al. · Diabetes Therapy, published online February 12, 2026 · DOI 10.1007/s13300-025-01838-0
-
Optimizing Continuous Glucose Monitoring Adoption in India: From Current Challenges to Future Solutions
The authors review why continuous glucose monitoring remains limited in India, citing low awareness, high costs, lack of reimbursement, poor availability outside major cities and alarm fatigue, and propose affordable devices, India-specific reimbursement and better education.
Kesavadev et al. · Diabetes Therapy, published online February 2, 2026 · DOI 10.1007/s13300-026-01842-y
-
Innovative Diabetes Therapies and Impact on Peripheral and Autonomic Diabetic Neuropathies: A State-of-the-Art Review
The authors review evidence that GLP-1 receptor agonists and SGLT2 inhibitors may protect nerves in diabetic neuropathy, and note that newer dual and triple receptor agonists could have added effects, although clinical data on them remain limited.
Vekic et al. · Diabetes Therapy, published online January 6, 2026 · DOI 10.1007/s13300-025-01828-2
Related journals
Questions about Diabetes Therapy
How can I read Diabetes Therapy articles without a subscription?
100% of Diabetes Therapy articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Diabetes Therapy articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Diabetes Therapy?
Diabetes Therapy’s NLM (PubMed) abbreviation is Diabetes Ther.
What is the ISSN of Diabetes Therapy?
The print ISSN is 1869-6953 and the online ISSN is 1869-6961.
What is the impact factor of Diabetes Therapy?
Diabetes Therapy’s Journal Impact Factor is 4.2 (2025), and its 5-year Impact Factor is 3.7, according to Springer Nature’s published metrics.
Is Diabetes Therapy open access?
Yes. Diabetes Therapy has published open access since 2010: 99 of the 99 articles it published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref.
Diabetes Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.
Start reading Diabetes Therapy today
One month free, then less than $2 a day. Diabetes Therapy, plus millions of articles from thousands of journals.






